추가 설명:
Prolgolimab is BIOCAD's original, fully human anti-PD-1 monoclonal antibody, developed for treating advanced melanoma, advanced NSCLC and metastatic cervical cancer. It is pending approval in Russia for melanoma from 2019, while BIOCAD pursues Phase III trials to support EU marketing authorisation.
평가 & 댓글 남기기